A method of preparing a Polygoni Milletii Rhizome tincture includes: preparing a first mixture; extracting the first mixture with 70-90% ethanol under reflux condition to obtain a first extract solution; preparing a second mixture; extracting the second mixture with 50-70% ethanol to obtain a second extract solution; and mixing the first extract solution with the second extract solution to obtain the polygoni milletii rhizome tincture. A method of preparing a Polygoni Milletii Rhizome poultice includes: reparing a Polygoni Milletii Rhizome mixture; mixing the Polygoni Milletii Rhizome mixture and a skin penetration enhancer in water; mixing a moisturizing agent and a binder in water; adding a thickener in water; mixing methylparaben and ethylparaben in 90% ethanol; mixing all solutions to form a mixture; and applying the mixture on a non-woven fabric cloth and drying to form the Polygoni Milletii Rhizome poultice.

A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.

A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.

The present invention provides a composition, for preventing or treating an inflammatory disease, comprising, as an active ingredient, a self-hydrolysis extract using a hydrolase in a plant cell from one or more plants selected from Pulsatilla koreana, Pulsatilla chinensis, Pulsatilla cernua, Anemone raddeana, Aralia elata, Akebia quinata, Lonicera species, Adonis amurensis, Hedera helix, Hedera colchica and Patrinia scabiosifolia, and/or additionally an angiogenesis inhibitor.

The present invention provides a composition, for preventing or treating an inflammatory disease, comprising, as an active ingredient, a self-hydrolysis extract using a hydrolase in a plant cell from one or more plants selected from Pulsatilla koreana, Pulsatilla chinensis, Pulsatilla cernua, Anemone raddeana, Aralia elata, Akebia quinata, Lonicera species, Adonis amurensis, Hedera helix, Hedera colchica and Patrinia scabiosifolia, and/or additionally an angiogenesis inhibitor.

Herbal compositions comprising dihydromyricetin (DHM) and methods of use. The herbal compositions include DHM in combination with other ingredients to form compositions that can significantly improve the quality and duration of sleep, reduce the time for onset of improved sleep quality and duration, and treat or alleviate the symptoms of sleep-related disorders and neurological conditions. The composition is a therapeutic alternative to drugs to alleviate sleep disorders and related symptoms and ailments.

Herbal compositions comprising dihydromyricetin (DHM) and methods of use. The herbal compositions include DHM in combination with other ingredients to form compositions that can significantly improve the quality and duration of sleep, reduce the time for onset of improved sleep quality and duration, and treat or alleviate the symptoms of sleep-related disorders and neurological conditions. The composition is a therapeutic alternative to drugs to alleviate sleep disorders and related symptoms and ailments.

A medicated drink for relieving stress and helping a person with insomnia to fall asleep faster. The medicated drink includes Cannabidiol (CBD); Melatonin; GABA (Gamma-Aminobutyric-acid); L-Theanine-Amino acid; Valerian Root-aqueous extract; and Water.

A medicated drink for relieving stress and helping a person with insomnia to fall asleep faster. The medicated drink includes Cannabidiol (CBD); Melatonin; GABA (Gamma-Aminobutyric-acid); L-Theanine-Amino acid; Valerian Root-aqueous extract; and Water.

A composition that includes at least one target supplement and at least one rehydration formulation is described. When the at least one target supplement is ingested as part of the composition, the bioavailability of at least one target supplement is enhanced as compared to when it is ingested separate from the composition. The at least one target supplement is absorbed more quickly and in a greater amount when it is ingested as part of the composition than when it is ingested separate from the composition. The composition also hydrates a subject more quickly.